LPHM
Lee Pharmaceuticals
Price:  
0.07 
USD
Volume:  
20,510.00
United States | Personal Products
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

LPHM WACC - Weighted Average Cost of Capital

The WACC of Lee Pharmaceuticals (LPHM) is 6.3%.

The Cost of Equity of Lee Pharmaceuticals (LPHM) is 6.30%.
The Cost of Debt of Lee Pharmaceuticals (LPHM) is 8.45%.

Range Selected
Cost of equity 5.40% - 7.20% 6.30%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 7.00% - 9.90% 8.45%
WACC 5.4% - 7.2% 6.3%
WACC

LPHM WACC calculation

Category Low High
Long-term bond rate 3.9% 4.4%
Equity market risk premium 4.6% 5.6%
Adjusted beta 0.34 0.41
Additional risk adjustments 0.0% 0.5%
Cost of equity 5.40% 7.20%
Tax rate 26.20% 27.00%
Debt/Equity ratio 0.29 0.29
Cost of debt 7.00% 9.90%
After-tax WACC 5.4% 7.2%
Selected WACC 6.3%

LPHM's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for LPHM:

cost_of_equity (6.30%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.34) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.